CompletedNCT00202007

Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia

Medication studyAges 18–65China

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations: Guangzhou, China · Wuhan, China and 3 more locationsSee all locations and recruitment
Activities: Medication described in the protocol
Compensation: Payment and expense reimbursement have not been verified.

Study clarity

Study start dateFebruary 2005

Recruitment status: Completed
Enrollment listed in the registry: 240
Sponsor: Otsuka Beijing Research Institute
Sponsor type: Research institute
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: China
Age range: From 18 Years to 65 Years
Official registry ID: NCT00202007
Official title: Show the full official title
A Multi-Center, Randomized, Double-Blind Study, Comparing With Risperidone, to Evaluate the Efficacy and Safety of Aripiprazole in the Treatment of Patients With Schizophrenia

Completed

Guangzhou · Wuhan · Nanjing

2 more locations

FAQ

Who is behind this study?

The study sponsor is Otsuka Beijing Research Institute, a research institute.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole tablet, 5-30mg/day, oral, 6 weeks and Risperidone tablet, 1-6mg/day, oral, 6 weeks.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.